Results of Week 52 ICONIC-LEAD Data From EADV

Patients receiving icotrokinra maintain excellent treatment responses over extended periods, with week 52 data demonstrating sustained efficacy across adult and adolescent populations. Nearly 90% of adult patients maintained PASI 75 responses through 1 full year of treatment; over 90% of adolescent patients sustained similar response levels. This durability addresses patient concerns about treatment effectiveness declining over time, a common worry expressed by individuals considering long-term psoriasis management.

Long-term response maintenance proves critical for patients managing psoriasis as a chronic, lifelong condition that may persist for decades. Many patients express anxiety about treatments losing effectiveness over time, often based on previous experiences with therapies that provided initial improvement followed by diminished results. The sustained efficacy data provide reassurance for patients considering oral treatment, demonstrating that initial improvements can be maintained with continued therapy.

Adolescent patients particularly benefit from oral treatment options that offer sustained efficacy with convenient once-daily administration, comparable to taking daily vitamins. The ease of use for younger patients eliminates injection-related challenges while providing reliable, long-term disease control throughout critical developmental years. Patients in this age group achieve excellent outcomes with simple oral administration, which supports adherence and consistent treatment throughout adolescence, when peer relationships and self-image concerns are particularly important.